stockrow
Friday 6 November 2026
Export RNTX’s income statement to Excel — free account
Rein Therapeutics Inc.
RNTX Healthcare Biotechnology
- EPS
- +64.3%
- Free cash flow
- −34.6%
Quarter to June 2026, against a year earlier
0.61
0.00
0.00%
Follow RNTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (18) | (23) | (32) | (29) | (21) | (26) | (27) | (16) | (64) | (51) | (50) | +12.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (18) | (23) | (32) | (29) | (21) | (26) | (27) | (16) | (63) | (50) | (50) | +11.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (842.93) | (60.80) | (42.80) | (24.00) | (12.20) | (5.80) | (6.02) | (3.42) | (3.51) | (1.96) | (1.72) | (49.0%) | ||||||
| Cash flow | (698.33) | (55.16) | (37.90) | (21.58) | (11.74) | (5.35) | (5.48) | (4.31) | (1.24) | (0.76) | (0.28) | (53.1%) | ||||||
| Capex | 0.00 | (0.38) | (6.00) | (0.12) | 0.12 | (0.02) | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (698.33) | (55.54) | (43.90) | (21.70) | (11.63) | (5.37) | (5.48) | (4.30) | (1.24) | (0.76) | (0.28) | (53.1%) | ||||||
| Book value | (5,200.28) | 128.42 | 26.60 | 13.08 | 6.98 | 9.89 | 4.10 | 1.50 | 0.52 | (1.10) | 0.15 | (60.9%) | ||||||
| Shares, m | 0 | 0 | 1 | 1 | 2 | 4 | 5 | 5 | 18 | 25 | 37 | +119.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (15) | (21) | (28) | (26) | (20) | (24) | (25) | (20) | (22) | (19) | (19) | +2.9% | |||||
| Capex | — | 0 | (4) | 0 | 0 | 0 | — | 0 | — | — | 0 | n/m | ||||||
| Free cash flow | (15) | (21) | (32) | (27) | (20) | (24) | (25) | (20) | (22) | (19) | (19) | +2.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 17 | 47 | 16 | 14 | 12 | 44 | 18 | 14 | 8 | (2) | 32 | n/m | |||||
| Net debt | (21) | (51) | (15) | (13) | (14) | (46) | (21) | (17) | (13) | (3) | (41) | (18.7%) | ||||||
| Shareholders’ equity | (112) | 48 | 20 | 16 | 12 | 44 | 19 | 7 | 9 | (28) | 10 | (14.2%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (165.28) | (60.62) | (76.02) | (103.44) | (98.83) | (80.73) | (77.54) | (24.58) | (74.77) | (115.51) | (80.62) | +49.8 pt | |||||
| ROIC | 0.00 | 0.00 | (472.26) | (674.20) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 56.86 | 70.76 | (93.62) | (164.77) | (150.00) | (93.33) | (87.42) | (123.34) | (772.80) | 533.38 | (753.55) | +476.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 13 | 23 | 13 | 8 | 9 | 6 | 15 | 11 | 10 | — | (4.4%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Rein Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | Compare |
| HRTX Heron Therapeutics, Inc. | $53.2M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALPS Alps Group Inc. | $52.3M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $52.0M | — | — | +1.25% | — | −19.58% | 75.82% | 0.00% |
Pay and ownership Proxy statement filed 8 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2023 | 0.00 | 0.00 | 28.65 |
Ownership
Directors and executive officers, together
1.50%
Bios Entities
5.80%
Voss Capital, LP
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement